PharmaTelevision - Rentschler Biotechnologie: Klaus B. Schoepe

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Rentschler Biotechnologie: Klaus B. Schoepe

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Klaus B. Schoepe, Senior Vice President Client Relations at Rentschler Biotechnologie

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

History of Rentschler Biotechnologie

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Munich at BIO-Europe 2010. On this show I have Klaus B. Schoepe , who is Senior Vice President of Client Relations at Rentschler Biotechnologie.

Klaus B. Schoepe :

Happy to be here.

Fintan Walton:

Klaus, Rentschler is now quite a famous company it's very well known as a company involved in manufacturing biologics particularly, but could you tell us just little bit about the history of Rentschler and how it developed over the years, because it's quite an old company?

Klaus B. Schoepe :

Indeed it is, I mean we were founded, you wouldn't believe this way back in 1927 obviously not as a biotech company, but as a traditional pharmaceutical company a local company founded by what was the grandfather of our current CEO together with his brother they developed the idea of producing medicines on an industrial level and came out with variety of what you would call today over the counter drugs which they produced and the company has been involved into all sorts of different areas after the war we were to some extend involved in vaccines and animal vaccines and out of that developed the idea in the 70's to get into interferons which was really the foundation of Rentschler Biotechnologie or Biotechnology as it is today and so we then had for more than 20-years history of interferon developments. We were the first company that ever got an interferon product approved worldwide in Germany and that was developed by made by Recombinant DNA technology but by cell culture of human cells which were induced to produce interferon and then that interferon was harvested and purified the product is still on the market called Fiblaferon in Germany as it is licensed for viral infections. Well then in the late 90's we sort off were looking strategical view what to do with this business and then we developed the concept of no longer going after own proprietary products but to take our assets, take our knowledge and everything and offer that to third parties as a service and so since then we've been providing services to the biotech and biopharmaceutical industry and that has laid the foundation of a very nice growth path for the company at that time we were less than a 100 people now we are more than 600, our revenues have gone up to close to 88 million euro nowadays. So this been a very nice and constant growth organic growth all over the years with tremendous expansion, new facilities and a lot of commitment from our shareholders which is still is the Rentschler family basically to invest all sorts of money's into this business at the same time we divested all the other business lines including what was the foundation of Rentschler as a company including our OTC products which went away in 2006. So now a days we are 100% CMO, 100% service company for the biopharmaceutical industry and we think this is a very good business position and we like what we do.

Fintan Walton:

Right, so but what's interesting about that history is how the company has adapted over time to the various market opportunities, so it is followed in the sense the pharmaceutical industry itself obviously the importance of biologics way back even in the 70's were important.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Klaus B Schoepe

Senior Vice President

Dr. Klaus B. Schoepe , Senior Vice President Projects, Rentschler Biotechnologie, Germany. Klaus B. Schoepe studied Chemistry and Pharmacy in Berlin, Freiburg and Heidelberg. He is a licensed pharmacist and obtained a Dr. rer. nat. in Biochemistry at the German Cancer Research Center (Heidelberg, Germany). He started his career in the pharmaceutical industry with Boehringer Mannheim GmbH. He subsequently worked for Hoffmann La Roche AG (Basel, Switzerland), ASTA Medica AG (Frankfurt/Main, Germany which later became Baxter Oncology GmbH) and Merckle GmbH (Ulm, Germany). In 2005 he joined Rentschler Biotechnologie GmbH. In 2007 he was appointed to his current position with responsibility for Project Management, Regulatory Affairs and Quality Assurance.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Rentschler Biotechnologie

Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 30 years experience in development, production and approval of biopharmaceuticals in compliance with international standards of good manufacturing practice (GMP, Good Manufacturing Practice). Rentschler Biotechnologie has nine independent GMP suites with volumes of 30, 50, 250, 500 and 2,500 liters to produce material for clinical trials (phase I to III) and for market supply. Rentschler also provides regulatory advice, protein analysis, quality control and the sterile filling of syringes and vials. The company employs about 500 people.